ArticleScience translational medicine2026

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Adam S Sperling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.